Polymorphisms of the CYP2C9 Gene are not Associated with Essential hypertension in Chinese Population

被引：0
|
作者：
Qing, Zhu [1 ,2 ]
Fu, Zhenyan [1 ,2 ]
Ma, Yitong [1 ,2 ]
机构：
[1] Xinjiang Med Univ, Dept Cardiol, Affiliated Hosp 1, Urumqi, Peoples R China
[2] Xinjiang Key Lab Cardiovasc Dis Res, Urumqi, Peoples R China
来源：
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY | 2014年 / 64卷 / 16期
关键词：
D O I：
10.1016/j.jacc.2014.06.100
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
GW25-e3134
引用
收藏
页码：C20 / C20
页数：1
相关论文
共 50 条
  • [21] CYP2C9 and CYP2C19 genetic polymorphisms:: frequencies in the south Indian population
    Jose, R
    Chandrasekaran, A
    Sam, SS
    Gerard, N
    Chanolean, S
    Abraham, BK
    Satyanarayanamoorthy, K
    Peter, A
    Rajagopal, K
    FUNDAMENTAL & CLINICAL PHARMACOLOGY, 2005, 19 (01) : 101 - 105
  • [22] Characterisation of CYP2C8, CYP2C9 and CYP2C19 polymorphisms in a Ghanaian population
    Kudzi, William
    Dodoo, Alexander N. O.
    Mills, Jeremy J.
    BMC MEDICAL GENETICS, 2009, 10
  • [23] Genetic polymorphisms of CYP2C9, CYP2C19, and CYP3A5 in Kosovar population
    Krasniqi, Valon
    Dimovski, Aleksandar
    Bytyqi, Hasime Qorraj
    Eftimov, Aleksandar
    Simicevic, Livija
    Bozina, Nada
    ARHIV ZA HIGIJENU RADA I TOKSIKOLOGIJU-ARCHIVES OF INDUSTRIAL HYGIENE AND TOXICOLOGY, 2017, 68 (03): : 180 - 184
  • [24] Association of CYP2C8, CYP2C9 and CYP2J2 gene polymorphisms with myocardial infarction in South Indian population
    Annan Sudarsan Arun Kumar
    Srinivasamurthy Suresh Kumar
    Gurusamy Umamaheswaran
    Ramasamy Kesavan
    Jayaraman Balachandar
    Chandrasekaran Adithan
    Pharmacological Reports, 2015, 67 : 97 - 101
  • [25] Association of CYP2C8, CYP2C9 and CYP2J2 gene polymorphisms with myocardial infarction in South Indian population
    Kumar, Annan Sudarsan Arun
    Kumar, Srinivasamurthy Suresh
    Umamaheswaran, Gurusamy
    Kesavan, Ramasamy
    Balachandar, Jayaraman
    Adithan, Chandrasekaran
    PHARMACOLOGICAL REPORTS, 2015, 67 (01) : 97 - 101
  • [26] Allele frequency distribution of CYP2C9*2 and CYP2C9*3 polymorphisms in six Mexican populations
    Castelan-Martinez, Osvaldo D.
    Hoyo-Vadillo, Carlos
    Sandoval-Garcia, Emmanuel
    Sandoval-Ramirez, Lucila
    Gonzalez-Ibarra, Miriam
    Solano-Solano, Gloria
    Gomez-Diaz, Rita A.
    Parra, Esteban J.
    Cruz, Miguel
    Valladares-Salgado, Adan
    GENE, 2013, 523 (02) : 167 - 172
  • [27] Impacts of CYP2C9 and CYP2C19 genetic polymorphisms on pharmacokinetics of gliclazide in Chinese subjects
    Zhang, Yifan
    Chen, Xiaoyan
    Lin, Nan
    Zhong, Dafang
    Si, Dayong
    Gu, Yingjie
    Zhou, Hui
    DRUG METABOLISM REVIEWS, 2006, 38 : 161 - 162
  • [28] CYP2C9, but not CYP2C19, polymorphisms affect the pharmacokinetics and pharmacodynamics of glyburide in Chinese subjects
    Yin, OQP
    Tomlinson, B
    Chow, MSS
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2005, 78 (04) : 370 - 377
  • [29] CYP2C9 allele variants in Chinese hypertension patients and healthy controls
    Yu, BN
    Luo, CH
    Wang, D
    Wang, A
    Li, Z
    Zhang, W
    Mo, W
    Zhou, HH
    CLINICA CHIMICA ACTA, 2004, 348 (1-2) : 57 - 61
  • [30] The relationship between CYP2C9 gene polymorphisms and azilsartan metabolism in vitro
    Bao, Su-Su
    Tang, Peng-Fei
    Zhou, Quan
    Shao, Chuan-Feng
    Xiao, Zhong-Xiang
    Cheng, Chen
    Cai, Jian-Ping
    Li, Yun-Lei
    EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY, 2025, 21 (01) : 95 - 103
12345